A PHASE 3, PROSPECTIVE, RANDOMIZED, OPEN-LABEL, ADAPTIVE GROUP SEQUENTIAL, MULTICENTER TRIAL WITH BLINDED ENDPOINT ASSESSMENT TO EVALUATE THE EFFICACY AND SAFETY OF TAK-330 FOR THE REVERSAL OF DIRECT ORAL FACTOR XA INHIBITOR-INDUCED ANTICOAGULATION IN PATIENTS REQUIRING URGENT SURGERY/INVASIVE PROCEDURE

Registry ID

TAK-330-3001

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

TAKEDA DEVELOPMENT CENTER AMERICAS INC

Start date

2024-12-05

Last update

2022-06-17

Conditions

• SURGERY

Related clinical trials

• A PHASE 3 PROSPECTIVE RANDOMISED CLINICAL TRIAL OF VMX-C001 VS USUAL PHARMACOLOGICAL CARE IN PATIENTS RECEIVING A FXA DIRECT ORAL ANTICOAGULANT (FXA DOAC) WHO REQUIRE URGENT SURGERY OR OTHER INVASIVE PROCEDURE THAT IS ASSOCIATED WITH A HIGH RISK OF BLEEDING, WITH OR WITHOUT PLANNED ADMINISTRATION OF HEPARIN (EQUILIBRIX-S)
• OPTIMIZING PATIENT-CENTRED OUTCOMES USING OPIOID MINIMIZATION STRATEGIES (OPUS) ANESTHESIA PILOT TRIAL
• BLEEDING REDUCTION IN ACUTE AND CHRONIC KIDNEY PATIENTS HAVING SURGERY (BRACKETS) PILOT TRIAL
• BUPIVACAINE WITH EPINEPHRINE VS SHAM INJECTIONS DURING ENDOSCOPIC SEPTOPLASTY: A DOUBLE BLIND, RANDOMIZED CONTROLLED TRIAL
• TRANSVERSUS ABDOMINIS PLANE BLOCKS WITH AND WITHOUT DEXAMETHASONE: A RANDOMIZED CLINICAL TRIAL IN MINIMALLY INVASIVE COLORECTAL SURGERY
• THE USE OF INDOCYANINE GREEN ANGIOGRAPHY IN PEDIATRIC COLORECTAL SURGERY: A FEASIBILITY

View on source registry